Last reviewed · How we verify

Humulin N plus Humulin R

Université NAZI BONI · FDA-approved active Small molecule

This combination of intermediate-acting (NPH) and rapid-acting insulin provides basal and prandial glucose control by facilitating cellular glucose uptake and metabolism.

This combination of intermediate-acting (NPH) and rapid-acting insulin provides basal and prandial glucose control by facilitating cellular glucose uptake and metabolism. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameHumulin N plus Humulin R
SponsorUniversité NAZI BONI
Drug classInsulin combination therapy
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Humulin N is an isophane (NPH) insulin suspension that provides long-acting basal insulin coverage over 24 hours. Humulin R is a regular (short-acting) insulin that provides rapid postprandial glucose control. Together, they mimic physiologic insulin secretion patterns in diabetic patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: